Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial.

Joffe G, Terevnikov V, Joffe M, Stenberg JH, Burkin M, Tiihonen J.

Schizophr Res. 2009 Mar;108(1-3):245-51. doi: 10.1016/j.schres.2008.12.002. Epub 2009 Jan 13.

PMID:
19144501
2.

Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study.

Stenberg JH, Terevnikov V, Joffe M, Tiihonen J, Tchoukhine E, Burkin M, Joffe G.

Int J Neuropsychopharmacol. 2010 May;13(4):433-41. doi: 10.1017/S1461145709990897. Epub 2009 Nov 27.

PMID:
19941694
3.

More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial.

Terevnikov V, Stenberg JH, Joffe M, Tiihonen J, Burkin M, Tchoukhine E, Joffe G.

Hum Psychopharmacol. 2010 Aug;25(6):431-8. doi: 10.1002/hup.1137.

PMID:
20737516
4.

Relationships between pharmacotherapy-induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotics combination trial.

Terevnikov V, Stenberg JH, Tiihonen J, Chukhin E, Joffe M, Burkin M, Joffe G.

Int J Neuropsychopharmacol. 2013 Aug;16(7):1661-6. doi: 10.1017/S146114571200137X. Epub 2012 Dec 10.

PMID:
23217660
5.

Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.

Berk M, Gama CS, Sundram S, Hustig H, Koopowitz L, D'Souza R, Malloy H, Rowland C, Monkhouse A, Monkhouse A, Bole F, Sathiyamoorthy S, Piskulic D, Dodd S.

Hum Psychopharmacol. 2009 Apr;24(3):233-8. doi: 10.1002/hup.1017.

PMID:
19330802
6.

Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase.

Terevnikov V, Stenberg JH, Tiihonen J, Joffe M, Burkin M, Tchoukhine E, Joffe G.

Hum Psychopharmacol. 2011 Apr;26(3):188-93. doi: 10.1002/hup.1189.

PMID:
21469215
7.

The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial.

Abbasi SH, Behpournia H, Ghoreshi A, Salehi B, Raznahan M, Rezazadeh SA, Rezaei F, Akhondzadeh S.

Schizophr Res. 2010 Feb;116(2-3):101-6. doi: 10.1016/j.schres.2009.11.008. Epub 2009 Dec 2.

PMID:
19959338
8.

The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study.

Zoccali R, Muscatello MR, Cedro C, Neri P, La Torre D, Spina E, Di Rosa AE, Meduri M.

Int Clin Psychopharmacol. 2004 Mar;19(2):71-6.

PMID:
15076014
10.

Adjunct mirtazapine for negative symptoms of schizophrenia.

Phan SV, Kreys TJ.

Pharmacotherapy. 2011 Oct;31(10):1017-30. doi: 10.1592/phco.31.10.1017. Review.

PMID:
21950644
11.

Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial.

Cho SJ, Yook K, Kim B, Choi TK, Lee KS, Kim YW, Lee JE, Suh S, Yook KH, Lee SH.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):208-11. doi: 10.1016/j.pnpbp.2010.11.006. Epub 2010 Nov 21.

PMID:
21095214
12.

More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia.

Stenberg JH, Terevnikov V, Joffe M, Tiihonen J, Tchoukhine E, Burkin M, Joffe G.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1080-6. doi: 10.1016/j.pnpbp.2011.03.004. Epub 2011 Mar 21.

PMID:
21402120
13.

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.

Citrome L, Meng X, Hochfeld M, Stahl SM.

Hum Psychopharmacol. 2012 Jan;27(1):24-32. doi: 10.1002/hup.1254. Epub 2011 Dec 7.

PMID:
22161738
14.

Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia--a path model investigation.

Stenberg JH, Terevnikov V, Joffe M, Tiihonen J, Chukhin E, Burkin M, Joffe G.

Neuropharmacology. 2013 Jan;64:248-53. doi: 10.1016/j.neuropharm.2012.06.028. Epub 2012 Jun 26.

PMID:
22750079
15.

Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia.

Vidal C, Reese C, Fischer BA, Chiapelli J, Himelhoch S.

Clin Schizophr Relat Psychoses. 2015 Summer;9(2):88-95. doi: 10.3371/CSRP.VIRE.030813. Epub 2013 Mar 14.

PMID:
23491969
16.

Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial.

Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A.

Biol Psychiatry. 2006 Jun 1;59(11):1071-7. Epub 2006 Feb 21.

PMID:
16497273
17.

Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study.

Poyurovsky M, Epshtein S, Fuchs C, Schneidman M, Weizman R, Weizman A.

J Clin Psychopharmacol. 2003 Jun;23(3):305-8.

PMID:
12826992
18.

Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine.

Delle Chiaie R, Salviati M, Fiorentini S, Biondi M.

Exp Clin Psychopharmacol. 2007 Dec;15(6):563-8. doi: 10.1037/1064-1297.15.6.563.

PMID:
18179309
19.

Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis).

Miyaoka T, Furuya M, Horiguchi J, Wake R, Hashioka S, Tohyama M, Mori N, Minabe Y, Iyo M, Ueno S, Ezoe S, Murotani K, Hoshino S, Seno H.

Psychopharmacology (Berl). 2015 Jan;232(1):155-64. doi: 10.1007/s00213-014-3645-8. Epub 2014 Jun 13.

PMID:
24923986
20.

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.

Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.

Arch Gen Psychiatry. 2005 Nov;62(11):1196-204.

PMID:
16275807

Supplemental Content

Support Center